NCT01842308 · REGISTRY CONDITION SEARCH

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2020-09-01

This phase I/II trial studies the side effects and best dose of carfilzomib when given together with melphalan and to see how well they work in treating patients with multiple myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving carfilzomib together with melphalan may kill more cancer cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Determine Maximum Tolerated Dose by the Number of Patients With a DLT Per Dose Level

→

outcome · POSTED

Percentage of Patients With Complete Responses, Defined as a Complete Response Noted as the Objective Status on Two Consecutive Evaluations (Phase II)

→

outcome · POSTED

Adverse Event Rate, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

→

outcome · POSTED

Complete Response Rate at Day 100

→

outcome · POSTED

Progression Free Percentage at 1 and 2 Years Post Registration

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Serum creatinine =\< 2 mg/dL * Absolute neutrophil count \>= 1000/uL * Platelet count \>= 50,000/uL * Hemoglobin \>= 8.0 g/dL * Diagnosis of symptomatic MM * Measurable disease of multiple myeloma at the time of baseline values for disease assessment as defined by at least one of the following: * Serum monoclonal protein \>= 1.0 g/dL * \>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis * Serum immunoglobulin free light chain \>=10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Bone marrow plasma cells \>= 30% * NOTE: For patients with no relapse prior to transplant, measurable disease at the time of diagnosis * NOTE: For patients who have had a disease relapse prior to transplant, measurable disease at the time of the most recent relapse immediately prior to transplant; NOTE: If the patient had treatment for the relapsed disease prior to transplant, the patient must have measurable disease at the time of relapse prior to this therapy * Patient is considered for autologous stem cell transplantation with full dose melphalan (200 mg/m\^2) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity) * Provide informed written consent * Ejection fraction \>= 45% * Corrected pulmonary diffusion capacity of greater than or equal to 50% * Forced expiratory volume in 1 second (FEV1) \>= 50% * Forced vital capacity (FVC) \>= 50% * Negative pregnancy test performed =\< 7 days prior to registration, for women of childbearing potential only * Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, Mayo Clinic Florida for treatment * Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up * Willing to provide blood and bone marrow samples for correlative research purposes Exclusion Criteria: * Prior autologous or allogeneic bone marrow/peripheral blood stem cell transplant * More than two prior regimens for therapy of MM * Myocardial infarction within 6 months prior to enrollment, or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; NOTE: Prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant * Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) I or II, hepatitis B virus (HBV), hepatitis C virus (HCV) * Other active malignancy \< 2 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer * Any of the following: * Pregnant women or women of reproductive capability who are unwilling to use effective contraception * Nursing women * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 28 days after stopping treatment * Other co-morbidity, which would interfere with patient's ability to participate in the trial, e.g. uncontrolled infection, uncompensated lung disease * Concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment * Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3. TRANSPLANT: Patients undergo autologous stem cell transplant on day 0.
intervention Names
Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Drug: Melphalan
label
Treatment
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment
description
Undergo autologous stem cell transplant
name
Autologous Bone Marrow Transplantation
other Names
ABMT
Autologous Bone Marrow Transplant
Autologous Marrow Transplantation
type
PROCEDURE
arm Group Labels
Treatment
description
Undergo autologous stem cell transplant
name
Autologous Hematopoietic Stem Cell Transplantation
other Names
Autologous Hematopoietic Cell Transplantation
Autologous Stem Cell Transplantation
type
PROCEDURE
arm Group Labels
Treatment
description
Given IV
name
Carfilzomib
other Names
Kyprolis
PR-171
type
DRUG
arm Group Labels
Treatment
description
Correlative studies
name
Laboratory Biomarker Analysis
type
OTHER
arm Group Labels
Treatment
description
Given IV
name
Melphalan
other Names
Alanine Nitrogen Mustard
CB-3025
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysin Phenylalanine mustard
L-Sarcolysine
Melphalanum
Phenylalanine Mustard
Phenylalanine Nitrogen Mustard
Sarcoclorin
Sarkolysin
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 50
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity(DLT) in at least one-third of patients. For this study, a DLT is any of the following during the first 2 cycles of treatment; Absolute neutrophil count engraftment\* delayed beyond day 21 or Platelet engraftment\* delayed beyond day 30, grade 3+ related sensory or motor neuropathy, or grade 4+ related non-neurologic or non-hematologic adverse event(excluding nausea, vomiting, and diarrhea. Reported below are the number of patients who experienced a DLT.
measure
Determine Maximum Tolerated Dose by the Number of Patients With a DLT Per Dose Level
time Frame
Up to day 30
description
The percentage of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success percentages will be calculated.
measure
Percentage of Patients With Complete Responses, Defined as a Complete Response Noted as the Objective Status on Two Consecutive Evaluations (Phase II)
time Frame
Up to 5 years

secondary Outcomes

description
These results are reported in the adverse events section. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
measure
Adverse Event Rate, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
time Frame
Up to 5 years
description
Complete response rate (CRR) is defined as the percentage of complete responses estimated by the total number of patients who achieve a complete response by day 100 post-transplant divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true complete response rate at day 100 will be calculated.
measure
Complete Response Rate at Day 100
time Frame
At day 100
description
Progression is an Increase of 25% from lowest value in any of the following (A "25% increase" refers to M protein, FLC and bone marrow results and does not refer to bone lesions, soft tissue plasmacytoma or hypercalcemia. The lowest value does not need to be a confirmed value. If the lowest serum Mprotein is ≥ 5 g/dL, an increase in serum M-protein of ≥ 1 g/dL is sufficient to define disease progression.), (In the case where a value is felt to be a spurious result per physician discretion (for example, a possible lab error), that value will not be considered when determining the lowest value.): Serum M-protein (absolute increase must be ≥ 0.5 g/dL) and/or Urine M-protein (absolute increase must be ≥ 200 mg/24 hrs) and/or If the only measurable disease is FLC, the difference between involved and uninvolved FLC levels (absolute increase must be\>10 mg/dL) and/or If the only measurable disease is BM, bone marrow PC percentage (absolute increase must be ≥ 10%) (Bone marrow criteria for PD
measure
Progression Free Percentage at 1 and 2 Years Post Registration
time Frame
At 1 year and 2 years

Full study description

brief Summary: This phase I/II trial studies the side effects and best dose of carfilzomib when given together with melphalan and to see how well they work in treating patients with multiple myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving carfilzomib together with melphalan may kill more cancer cells.
detailed Description: PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of carfilzomib that can be added to high dose melphalan as part of conditioning chemotherapy for myeloma. (Phase I) II. To determine the efficacy of the combination in patients with myeloma undergoing stem cell transplantation, as defined by achievement of complete response (CR). (Phase II) SECONDARY OBJECTIVES: I. To examine the toxicities associated with addition of carfilzomib to high dose melphalan in patients with multiple myeloma (MM). II. To determine the progression free rate at 1 and 2 years post registration. TERTIARY OBJECTIVES: I. To determine the proportion of patients achieving a minimal residual disease (MRD) negative status. II. To assess the HevyLite assay prior to and during treatment. OUTLINE: This is a phase I, dose-escalation study of carfilzomib followed by a phase II study. CONDITIONING: Patients receive carfilzomib intravenously (IV) over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3. TRANSPLANT: Patients undergo autologous stem cell transplant on day 0. After completion of study treatment, patients are followed up at day 30, day 100, and then every 90 days for up to 5 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-1dfdd288f9e33ca54e6c
requested nct id
NCT01842308
primary nct id
NCT01842308
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
d2e7bed5665b251b0c21110f4a3ebaa4e6d42b4d91edd676f2ff741cdb06fcea
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-1dfdd288f9e33ca54e6c
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01842308
occurrences
context exact
NCT01842308
end
11
exact text
NCT01842308
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/156/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
27f51d388a0022c36f27b839a8a0a8eab1fb9a54d8e66ba42bae7ede8f4b212f
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice